Vaniprevir with pegylated interferon alpha‐2a and ribavirin in treatment‐naïve patients with chronic hepatitis C: A randomized phase II study
Michael P. Manns, Edward Gane, Maribel Rodriguez‐Torres, Albrecht Stoehr, Chau‐Ting Yeh, Patrick Marcellin, Richard T. Wiedmann, Peggy M. Hwang, Luzelena Caro, Richard J.O. Barnard, Andrew W. Lee, for the MK‐7009 Protocol 007 Study Group – 2 April 2012 – Vaniprevir (MK‐7009) is a macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. The aim of the present phase II study was to examine virologic response rates with vaniprevir in combination with pegylated interferon alpha‐2a (Peg‐IFN‐α‐2a) plus ribavirin (RBV).